Clemizole - Eiger BioPharmaceuticals

Drug Profile

Clemizole - Eiger BioPharmaceuticals

Alternative Names: Clemizole hydrochloride

Latest Information Update: 06 Mar 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eiger BioPharmaceuticals
  • Developer Eiger BioPharmaceuticals; Eiger BioPharmaceuticals, Inc.
  • Class Antiallergics; Antiepileptic drugs; Antihistamines; Benzimidazoles; Small molecules
  • Mechanism of Action Hepatitis C virus NS4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Liver cancer
  • Discontinued Hepatitis C

Most Recent Events

  • 06 Mar 2017 Discontinued - Phase-I for Hepatitis C in Australia and New Zealand (PO)
  • 13 Feb 2017 Phase-II clinical trials in liver cancer in Turkey (PO) (NCT03069508)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Hepatitis-C in Australia (PO, Capsule)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top